The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
The BATTLE Trial: Personalizing Therapy for Lung Cancer
Open accessAbstract
The Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) trial represents the first completed prospective, biopsy-mandated, biomarker-based, adaptively randomized study in 255 pretreated lung cancer patients. Following an initial equal randomization period, chemorefractory non–small cell lung cancer (NSCLC) patients were adaptively randomized to erlotinib, vandetanib, erlotinib plus bexarotene, or sorafenib, based on relevant molecular biomarkers analyzed in fresh core needle biopsy specimens. Overall results include a 46% 8-week disease control rate (primary end point), confirm prespecified hypotheses, and show an impressive benefit from sorafenib among mutant-KRAS patients. BATTLE establishes the feasibility of a new paradigm for a personalized approach to lung cancer clinical trials. (ClinicalTrials.gov numbers: NCT00409968, NCT00411671, NCT00411632, NCT00410059, and NCT00410189.) Significance: The BATTLE study is the first completed prospective, adaptively randomized study in heavily pretreated NSCLC patients that mandated tumor profiling with “real-time” biopsies, taking a substantial step toward realizing personalized lung cancer therapy by integrating real-time molecular laboratory findings in delineating specific patient populations for individualized treatment. Cancer Discovery; 1(1); 44–53. © 2011 AACR. Read the Commentary on this article by Sequist et al., p. 14 Read the Commentary on this article by Rubin et al., p. 17 This article is highlighted in the In This Issue feature, p. 4
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Jemal, A., Siegel, R., Xu, J., & Ward, E. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20073 · Cited by 12,596
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Self-citationGefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419 · cited 1×
“Our overall response rate of 4% is reflective of a heavily pretreated NSCLC population and consistent with other published studies in this population (5, 9, 14).”
ResultScagliotti, G. V., Parikh, P., von Pawel, J., Biesma, B., Vansteenkiste, J., Manegold, C., Serwatowski, P., Gatzemeier, U., Digumarti, R., Zukin, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0375 · Cited by 3,203
Self-citationHerbst, R. S., Heymach, J. V., & Lippman, S. M. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0802714 · Cited by 2,389
Self-citationScreening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
Rosell, R., Moran, T., Queralt, C., Porta, R., Cardenal, F., Camps, C., Majem, M., Lopez-Vivanco, G., Isla, D., Provencio, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904554 · Cited by 2,373
Cited by
The biology and management of non-small cell lung cancer
Herbst, R. S., Morgensztern, D., & Boshoff, C. (2018) · Nature · doi:10.1038/nature25183 · Cited by 4,891
Self-citationApplications of machine learning in drug discovery and development
Vamathevan, J., Clark, D., Czodrowski, P., Dunham, I., Ferran, E., Lee, G., Li, B., Madabhushi, A., Shah, P., Spitzer, M., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0024-5 · Cited by 3,228
Frampton, G. M., Fichtenholtz, A., Otto, G. A., Wang, K., Downing, S. R., He, J., Schnall-Levin, M., White, J., Sanford, E. M., An, P., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2696 · Cited by 2,157
Cyclin D as a therapeutic target in cancer
Musgrove, E. A., Caldon, C. E., Barraclough, J., Stone, A., & Sutherland, R. L. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3090 · Cited by 1,370
Lessons from the Cancer Genome
Garraway, L. A., & Lander, E. S. (2013) · Cell · doi:10.1016/j.cell.2013.03.002 · Cited by 1,308
Tumour heterogeneity in the clinic
Bedard, P. L., Hansen, A. R., Ratain, M. J., & Siu, L. L. (2013) · Nature · doi:10.1038/nature12627 · Cited by 1,211
Toward personalized treatment approaches for non-small-cell lung cancer
Wang, M., Herbst, R. S., & Boshoff, C. (2021) · Nature Medicine · doi:10.1038/s41591-021-01450-2 · Cited by 1,093
Self-citationByers, L. A., Diao, L., Wang, J., Saintigny, P., Girard, L., Peyton, M., Shen, L., Fan, Y., Giri, U., Tumula, P. K., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1558 · Cited by 1,059
Self-citationThe quest to overcome resistance to EGFR-targeted therapies in cancer
Chong, C. R., & Jänne, P. A. (2013) · Nature Medicine · doi:10.1038/nm.3388 · Cited by 1,052
Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both
Woodcock, J., & LaVange, L. M. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1510062 · Cited by 1,020
Geeleher, P., Cox, N. J., & Huang, R. S. (2014) · Genome Biology · doi:10.1186/gb-2014-15-3-r47 · Cited by 890
Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations
Hunter, J. C., Manandhar, A., Carrasco, M. A., Gurbani, D., Gondi, S., & Westover, K. D. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0203 · Cited by 786
Machine Learning in Drug Discovery: A Review
Dara, S., Dhamercherla, S., Jadav, S. S., Babu, C. M., & Ahsan, M. J. (2022) · Artificial Intelligence Review · doi:10.1007/s10462-021-10058-4 · Cited by 792
Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations
Tan, A. C., & Tan, D. S. W. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01626 · Cited by 779
Review of precision cancer medicine: Evolution of the treatment paradigm
Tsimberidou, A. M., Fountzilas, E., Nikanjam, M., & Kurzrock, R. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102019 · Cited by 756
Deng, N., Goh, L. K., Wang, H., Das, K., Tao, J., Tan, I. B., Zhang, S., Lee, M., Wu, J., Lim, K. H., et al. (2012) · Gut · doi:10.1136/gutjnl-2011-301839 · Cited by 645
Small cell lung cancer: Where do we go from here?
Byers, L. A., & Rudin, C. M. (2015) · Cancer · doi:10.1002/cncr.29098 · Cited by 636
Ihle, N. T., Byers, L. A., Kim, E. S., Saintigny, P., Lee, J. J., Blumenschein, G. R., Tsao, A., Liu, S., Larsen, J. E., Wang, J., et al. (2012) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djr523 · Cited by 532
Self-citationLi, T., Kung, H.-J., Mack, P. C., & Gandara, D. R. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.3753 · Cited by 518
Targeting the MAPK pathway in KRAS-driven tumors
Drosten, M., & Barbacid, M. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.013 · Cited by 512
Park, J. J. H., Siden, E., Zoratti, M. J., Dron, L., Harari, O., Singer, J., Lester, R. T., Thorlund, K., & Mills, E. J. (2019) · Trials · doi:10.1186/s13063-019-3664-1 · Cited by 441
Lou, Y., Diao, L., Cuentas, E. R. P., Denning, W. L., Chen, L., Fan, Y. H., Byers, L. A., Wang, J., Papadimitrakopoulou, V. A., Behrens, C., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1434 · Cited by 438
Self-citationRETRACTED ARTICLE: Artificial intelligence and machine learning in precision and genomic medicine
Quazi, S. (2022) · Medical Oncology · doi:10.1007/s12032-022-01711-1 · Cited by 432
RetractedSholl, L. M., Aisner, D. L., Varella-Garcia, M., Berry, L. D., Dias-Santagata, D., Wistuba, I. I., Chen, H., Fujimoto, J., Kugler, K., Franklin, W. A., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000516 · Cited by 430
Self-citationGenetic alterations defining NSCLC subtypes and their therapeutic implications
Pikor, L. A., Ramnarine, V. R., Lam, S., & Lam, W. L. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.07.025 · Cited by 375
An integrin β3-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition
Seguin, L., Kato, S., Franovic, A., Camargo, M. F., Lesperance, J., Elliott, K. C., Yebra, M., Mielgo, A., Lowy, A. M., Husain, H., et al. (2014) · Nature Cell Biology · doi:10.1038/ncb2953 · Cited by 374
Self-citationJackson, S. E., & Chester, J. D. (2015) · International Journal of Cancer · doi:10.1002/ijc.28940 · Cited by 369
Sundaresan, T. K., Sequist, L. V., Heymach, J. V., Riely, G. J., Jänne, P. A., Koch, W. H., Sullivan, J. P., Fox, D. B., Maher, R., Muzikansky, A., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1031 · Cited by 347
Self-citationSchwaederle, M., Zhao, M., Lee, J. J., Lazar, V., Leyland-Jones, B., Schilsky, R. L., Mendelsohn, J., & Kurzrock, R. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.2129 · Cited by 348
Self-citationPrecision medicine for metastatic breast cancer—limitations and solutions
Arnedos, M., Vicier, C., Loi, S., Lefebvre, C., Michiels, S., Bonnefoi, H., & Andre, F. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.123 · Cited by 317
Medical therapies for hepatocellular carcinoma: a critical view of the evidence
Villanueva, A., Hernandez-Gea, V., & Llovet, J. M. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2012.199 · Cited by 314
Clinical trial design in the era of precision medicine
Fountzilas, E., Tsimberidou, A. M., Vo, H. H., & Kurzrock, R. (2022) · Genome Medicine · doi:10.1186/s13073-022-01102-1 · Cited by 305
KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target
Román, M., Baraibar, I., López, I., Nadal, E., Rolfo, C., Vicent, S., & Gil-Bazo, I. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0789-x · Cited by 301
Ellison, G., Zhu, G., Moulis, A., Dearden, S., Speake, G., & McCormack, R. (2013) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2012-201194 · Cited by 301
Wilkerson, M. D., Yin, X., Walter, V., Zhao, N., Cabanski, C. R., Hayward, M. C., Miller, C. R., Socinski, M. A., Parsons, A. M., Thorne, L. B., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036530 · Cited by 298
Patient-centric trials for therapeutic development in precision oncology
Biankin, A. V., Piantadosi, S., & Hollingsworth, S. J. (2015) · Nature · doi:10.1038/nature15819 · Cited by 282
Bhat, G. R., Sethi, I., Sadida, H. Q., Rah, B., Mir, R., Algehainy, N., Albalawi, I. A., Masoodi, T., Subbaraj, G. K., Jamal, F., et al. (2024) · Cancer and Metastasis Reviews · doi:10.1007/s10555-024-10172-z · Cited by 281
Precision Oncology: Who, How, What, When, and When Not?
Schwartzberg, L., Kim, E. S., Liu, D., & Schrag, D. (2017) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_174176 · Cited by 278
Self-citationRenfro, L. A., & Sargent, D. J. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw413 · Cited by 271
Lissanu Deribe, Y., Sun, Y., Terranova, C., Khan, F., Martinez-Ledesma, J., Gay, J., Gao, G., Mullinax, R. A., Khor, T., Feng, N., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0019-5 · Cited by 268
Self-citationOnline Decision Making with High-Dimensional Covariates
Bastani, H., & Bayati, M. (2020) · Operations Research · doi:10.1287/opre.2019.1902 · Cited by 263
Lopez-Chavez, A., Thomas, A., Rajan, A., Raffeld, M., Morrow, B., Kelly, R., Carter, C. A., Guha, U., Killian, K., Lau, C. C., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.2007 · Cited by 233
Gerber, D. E., Camidge, D. R., Morgensztern, D., Cetnar, J., Kelly, R. J., Ramalingam, S. S., Spigel, D. R., Jeong, W., Scaglioni, P. P., Zhang, S., et al. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2019.10.033 · Cited by 167
Development of an Immune-Pathology Informed Radiomics Model for Non-Small Cell Lung Cancer
Tang, C., Hobbs, B., Amer, A., Li, X., Behrens, C., Canales, J. R., Cuentas, E. P., Villalobos, P., Fried, D., Chang, J. Y., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-20471-5 · Cited by 154
Self-citationNilsson, M. B., Sun, H., Diao, L., Tong, P., Liu, D., Li, L., Fan, Y., Poteete, A., Lim, S.-O., Howells, K., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aao4307 · Cited by 146
Self-citationRello, J., van Engelen, T. S. R., Alp, E., Calandra, T., Cattoir, V., Kern, W. V., Netea, M. G., Nseir, S., Opal, S. M., van de Veerdonk, F. L., et al. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2018.03.011 · Cited by 143
Drug development and clinical trials—the path to an approved cancer drug
Rubin, E. H., & Gilliland, D. G. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.22 · Cited by 135
Genetically Engineered Mouse Models: Closing the Gap between Preclinical Data and Trial Outcomes
Singh, M., Murriel, C. L., & Johnson, L. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2786 · Cited by 125
A RAS Renaissance: Emerging Targeted Therapies for KRAS-Mutated Non–Small Cell Lung Cancer
Vasan, N., Boyer, J. L., & Herbst, R. S. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1762 · Cited by 102
Self-citationTNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancer
Gong, K., Guo, G., Gerber, D. E., Gao, B., Peyton, M., Huang, C., Minna, J. D., Hatanpaa, K. J., Kernstine, K., Cai, L., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96148 · Cited by 98
Self-citationPrediction of anti-cancer nanotherapy efficacy by imaging
Miller, M. A., Arlauckas, S., & Weissleder, R. (2017) · Nanotheranostics · doi:10.7150/ntno.20564 · Cited by 74
Dimairo, M., Pallmann, P., Wason, J., Todd, S., Jaki, T., Julious, S. A., Mander, A. P., Weir, C. J., Koenig, F., Walton, M. K., et al. (2020) · Trials · doi:10.1186/s13063-020-04334-x · Cited by 58
Arguing for Adaptive Clinical Trials in Sepsis
Talisa, V. B., Yende, S., Seymour, C. W., & Angus, D. C. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01502 · Cited by 52
Everolimus prolonged survival in transgenic mice with EGFR-driven lung tumors
Yasugi, M., Takigawa, N., Ochi, N., Ohashi, K., Harada, D., Ninomiya, T., Murakami, T., Honda, Y., Ichihara, E., Tanimoto, M., et al. (2014) · Experimental Cell Research · doi:10.1016/j.yexcr.2014.04.012 · Cited by 6
Metadata
- Authors
- Kim, E. S., Herbst, R. S., Wistuba, I. I., Lee, J. J., Blumenschein, G. R., Tsao, A., Stewart, D. J., Hicks, M. E., Erasmus, J., Gupta, S., Alden, C. M., Liu, S., Tang, X., Khuri, F. R., Tran, H. T., Johnson, B. E., Heymach, J. V., Mao, L., Fossella, F., Kies, M. S., Papadimitrakopoulou, V., Davis, S. E., Lippman, S. M., & Hong, W. K.
- Venue
- Cancer Discovery
- Published
- 2011-06-01
- Volume
- 1
- Issue
- 1
- Pages
- 44-53
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W1969525589
- Cited by
- 889
- References
- 28
- FWCI
- 69.78
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.